Frontiers in Oncology (May 2021)
Development of an Aerobic Glycolysis Index for Predicting the Sorafenib Sensitivity and Prognosis of Hepatocellular Carcinoma
- Yu Pan,
- Yu Pan,
- Yu Pan,
- Yu Pan,
- Yu Pan,
- Yu Pan,
- Geng-yuan Hu,
- Geng-yuan Hu,
- Geng-yuan Hu,
- Shi Jiang,
- Shi Jiang,
- Shi Jiang,
- Shi Jiang,
- Shi Jiang,
- Shi Jiang,
- Shun-jie Xia,
- Shun-jie Xia,
- Shun-jie Xia,
- Shun-jie Xia,
- Shun-jie Xia,
- Shun-jie Xia,
- Hendi Maher,
- Hendi Maher,
- Hendi Maher,
- Hendi Maher,
- Hendi Maher,
- Hendi Maher,
- Zhong-jie Lin,
- Zhong-jie Lin,
- Zhong-jie Lin,
- Zhong-jie Lin,
- Zhong-jie Lin,
- Zhong-jie Lin,
- Qi-jiang Mao,
- Qi-jiang Mao,
- Qi-jiang Mao,
- Qi-jiang Mao,
- Qi-jiang Mao,
- Qi-jiang Mao,
- Jie Zhao,
- Jie Zhao,
- Jie Zhao,
- Jie Zhao,
- Jie Zhao,
- Liu-xin Cai,
- Liu-xin Cai,
- Liu-xin Cai,
- Liu-xin Cai,
- Liu-xin Cai,
- Ying-hua Xu,
- Jun-jie Xu,
- Jun-jie Xu,
- Jun-jie Xu,
- Jun-jie Xu,
- Jun-jie Xu,
- Xiu-jun Cai,
- Xiu-jun Cai,
- Xiu-jun Cai,
- Xiu-jun Cai,
- Xiu-jun Cai
Affiliations
- Yu Pan
- Department of General Surgery, Sir Run-Run Shaw Hospital, Zhejiang University, Hangzhou, China
- Yu Pan
- Key Laboratory of Laparoscopic Technology of Zhejiang Province, Hangzhou, China
- Yu Pan
- Zhejiang Minimal Invasive Diagnosis and Treatment Technology Research Center of Severe Hepatobiliary Disease, Hangzhou, China
- Yu Pan
- Zhejiang Research and Development Engineering Laboratory of Minimally Invasive Technology and Equipment, Hangzhou, China
- Yu Pan
- Zhejiang University Cancer Center, Hangzhou, China
- Yu Pan
- School of Medicine, Zhejiang University, Hangzhou, China
- Geng-yuan Hu
- Zhejiang University Cancer Center, Hangzhou, China
- Geng-yuan Hu
- School of Medicine, Zhejiang University, Hangzhou, China
- Geng-yuan Hu
- Department of Gastrointestinal Surgery, Shaoxing People's Hospital, Shaoxing Hospital of Zhejiang University, Shaoxing, China
- Shi Jiang
- Department of General Surgery, Sir Run-Run Shaw Hospital, Zhejiang University, Hangzhou, China
- Shi Jiang
- Key Laboratory of Laparoscopic Technology of Zhejiang Province, Hangzhou, China
- Shi Jiang
- Zhejiang Minimal Invasive Diagnosis and Treatment Technology Research Center of Severe Hepatobiliary Disease, Hangzhou, China
- Shi Jiang
- Zhejiang Research and Development Engineering Laboratory of Minimally Invasive Technology and Equipment, Hangzhou, China
- Shi Jiang
- Zhejiang University Cancer Center, Hangzhou, China
- Shi Jiang
- School of Medicine, Zhejiang University, Hangzhou, China
- Shun-jie Xia
- Department of General Surgery, Sir Run-Run Shaw Hospital, Zhejiang University, Hangzhou, China
- Shun-jie Xia
- Key Laboratory of Laparoscopic Technology of Zhejiang Province, Hangzhou, China
- Shun-jie Xia
- Zhejiang Minimal Invasive Diagnosis and Treatment Technology Research Center of Severe Hepatobiliary Disease, Hangzhou, China
- Shun-jie Xia
- Zhejiang Research and Development Engineering Laboratory of Minimally Invasive Technology and Equipment, Hangzhou, China
- Shun-jie Xia
- Zhejiang University Cancer Center, Hangzhou, China
- Shun-jie Xia
- School of Medicine, Zhejiang University, Hangzhou, China
- Hendi Maher
- Department of General Surgery, Sir Run-Run Shaw Hospital, Zhejiang University, Hangzhou, China
- Hendi Maher
- Key Laboratory of Laparoscopic Technology of Zhejiang Province, Hangzhou, China
- Hendi Maher
- Zhejiang Minimal Invasive Diagnosis and Treatment Technology Research Center of Severe Hepatobiliary Disease, Hangzhou, China
- Hendi Maher
- Zhejiang Research and Development Engineering Laboratory of Minimally Invasive Technology and Equipment, Hangzhou, China
- Hendi Maher
- Zhejiang University Cancer Center, Hangzhou, China
- Hendi Maher
- School of Medicine, Zhejiang University, Hangzhou, China
- Zhong-jie Lin
- Department of General Surgery, Sir Run-Run Shaw Hospital, Zhejiang University, Hangzhou, China
- Zhong-jie Lin
- Key Laboratory of Laparoscopic Technology of Zhejiang Province, Hangzhou, China
- Zhong-jie Lin
- Zhejiang Minimal Invasive Diagnosis and Treatment Technology Research Center of Severe Hepatobiliary Disease, Hangzhou, China
- Zhong-jie Lin
- Zhejiang Research and Development Engineering Laboratory of Minimally Invasive Technology and Equipment, Hangzhou, China
- Zhong-jie Lin
- Zhejiang University Cancer Center, Hangzhou, China
- Zhong-jie Lin
- School of Medicine, Zhejiang University, Hangzhou, China
- Qi-jiang Mao
- Department of General Surgery, Sir Run-Run Shaw Hospital, Zhejiang University, Hangzhou, China
- Qi-jiang Mao
- Key Laboratory of Laparoscopic Technology of Zhejiang Province, Hangzhou, China
- Qi-jiang Mao
- Zhejiang Minimal Invasive Diagnosis and Treatment Technology Research Center of Severe Hepatobiliary Disease, Hangzhou, China
- Qi-jiang Mao
- Zhejiang Research and Development Engineering Laboratory of Minimally Invasive Technology and Equipment, Hangzhou, China
- Qi-jiang Mao
- Zhejiang University Cancer Center, Hangzhou, China
- Qi-jiang Mao
- School of Medicine, Zhejiang University, Hangzhou, China
- Jie Zhao
- Department of General Surgery, Sir Run-Run Shaw Hospital, Zhejiang University, Hangzhou, China
- Jie Zhao
- Key Laboratory of Laparoscopic Technology of Zhejiang Province, Hangzhou, China
- Jie Zhao
- Zhejiang Minimal Invasive Diagnosis and Treatment Technology Research Center of Severe Hepatobiliary Disease, Hangzhou, China
- Jie Zhao
- Zhejiang Research and Development Engineering Laboratory of Minimally Invasive Technology and Equipment, Hangzhou, China
- Jie Zhao
- Zhejiang University Cancer Center, Hangzhou, China
- Liu-xin Cai
- Department of General Surgery, Sir Run-Run Shaw Hospital, Zhejiang University, Hangzhou, China
- Liu-xin Cai
- Key Laboratory of Laparoscopic Technology of Zhejiang Province, Hangzhou, China
- Liu-xin Cai
- Zhejiang Minimal Invasive Diagnosis and Treatment Technology Research Center of Severe Hepatobiliary Disease, Hangzhou, China
- Liu-xin Cai
- Zhejiang Research and Development Engineering Laboratory of Minimally Invasive Technology and Equipment, Hangzhou, China
- Liu-xin Cai
- Zhejiang University Cancer Center, Hangzhou, China
- Ying-hua Xu
- Department of Oncology, Sir Run-Run Shaw Hospital, Zhejiang University, Hangzhou, China
- Jun-jie Xu
- Department of General Surgery, Sir Run-Run Shaw Hospital, Zhejiang University, Hangzhou, China
- Jun-jie Xu
- Key Laboratory of Laparoscopic Technology of Zhejiang Province, Hangzhou, China
- Jun-jie Xu
- Zhejiang Minimal Invasive Diagnosis and Treatment Technology Research Center of Severe Hepatobiliary Disease, Hangzhou, China
- Jun-jie Xu
- Zhejiang Research and Development Engineering Laboratory of Minimally Invasive Technology and Equipment, Hangzhou, China
- Jun-jie Xu
- Zhejiang University Cancer Center, Hangzhou, China
- Xiu-jun Cai
- Department of General Surgery, Sir Run-Run Shaw Hospital, Zhejiang University, Hangzhou, China
- Xiu-jun Cai
- Key Laboratory of Laparoscopic Technology of Zhejiang Province, Hangzhou, China
- Xiu-jun Cai
- Zhejiang Minimal Invasive Diagnosis and Treatment Technology Research Center of Severe Hepatobiliary Disease, Hangzhou, China
- Xiu-jun Cai
- Zhejiang Research and Development Engineering Laboratory of Minimally Invasive Technology and Equipment, Hangzhou, China
- Xiu-jun Cai
- Zhejiang University Cancer Center, Hangzhou, China
- DOI
- https://doi.org/10.3389/fonc.2021.637971
- Journal volume & issue
-
Vol. 11
Abstract
Hepatocellular carcinoma (HCC) is a deadly tumor with high heterogeneity. Aerobic glycolysis is a common indicator of tumor growth and plays a key role in tumorigenesis. Heterogeneity in distinct metabolic pathways can be used to stratify HCC into clinically relevant subgroups, but these have not yet been well-established. In this study, we constructed a model called aerobic glycolysis index (AGI) as a marker of aerobic glycolysis using genomic data of hepatocellular carcinoma from The Cancer Genome Atlas (TCGA) project. Our results showed that this parameter inferred enhanced aerobic glycolysis activity in tumor tissues. Furthermore, high AGI is associated with poor tumor differentiation and advanced stages and could predict poor prognosis including reduced overall survival and disease-free survival. More importantly, the AGI could accurately predict tumor sensitivity to Sorafenib therapy. Therefore, the AGI may be a promising biomarker that can accurately stratify patients and improve their treatment efficacy.
Keywords
